# Efficacy and Safety Study of Mepolizumab Adjunctive Therapy in Subjects With Severe Uncontrolled Refractory Asthma

> **NCT01691521** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 580 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** Mepolizumab IV
- **DRUG:** Mepolizumab SC
- **DRUG:** IV Placebo
- **DRUG:** SC Placebo

## Key facts

- **NCT ID:** NCT01691521
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-10-08
- **Primary completion:** 2014-01-01
- **Final completion:** 2014-01-18
- **Target enrollment:** 580 (ACTUAL)
- **Last updated:** 2018-08-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01691521

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01691521, "Efficacy and Safety Study of Mepolizumab Adjunctive Therapy in Subjects With Severe Uncontrolled Refractory Asthma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01691521. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*